Beta Thalassemia Therapies

Jan 21, 2022

Beta Thalassemia (β-Thalassemia) is a blood disorder characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin ana...

Dec 19, 2019

Global Therapeutics and Syros Pharmaceuticals have teamed up to move forward to discover, develop and market novel Sickle cell disease and beta-thalassemia therapies.  Inherited blood disorders affect millions of people worldwide. As per NIH, Sickle cell disease affects around 70,000 to 80,000 Americans, wh...